Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02436447
Recruitment Status : Completed
First Posted : May 6, 2015
Last Update Posted : November 18, 2015
Sponsor:
Information provided by (Responsible Party):
Stealth BioTherapeutics Inc.

Brief Summary:
This study is a Phase 1, open-label, parallel group, multiple dose study, in subjects over 18 years, to evaluate the safety, tolerability, and pharmacokinetics of one-hour intravenous infusion of MTP-131 administered for 7 consecutive days. Twenty-four subjects are planned to be enrolled into 4 cohorts of varying renal function, with each cohort consisting of 6 subjects.

Condition or disease Intervention/treatment Phase
Normal and Impaired Renal Function Drug: MTP-131 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, 7 Day Repeat Dose, Parallel-Group, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Intravenous Infusion of MTP-131 Administered in Subjects With Impaired Renal Function
Study Start Date : May 2015
Actual Primary Completion Date : July 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Tests

Arm Intervention/treatment
Experimental: Normal renal function Drug: MTP-131
MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.

Experimental: Mild renal impairment Drug: MTP-131
MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.

Experimental: Moderate renal impairment Drug: MTP-131
MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment

Experimental: Severe renal impairment Drug: MTP-131
MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment




Primary Outcome Measures :
  1. Mean peak plasma concentration (Cmax) of MTP-131 (ng/ml) in each cohort [ Time Frame: Assessed up to Day 14 ]

Secondary Outcome Measures :
  1. Incidence of Adverse Events [ Time Frame: Assessed up to Day 14 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject is ≥18 years-of-age at the Screening Visit.
  • Subject has signed an ICF before any study specific procedures are performed.
  • Subjects selected for each cohort must satisfy the following creatinine clearance (CLCR) criteria (as determined by 24 hour urine collection and analysis):

    • Cohort 1 - Normal Renal Function, 24 hour CLCR ≥ 90 mL/min
    • Cohort 2 - Mild renal impairment, 24 hour CLCR ≥ 60-89 mL/min
    • Cohort 3 - Moderate renal impairment, 24 hour CLCR ≥ 30-59 mL/min
    • Cohort 4 - Severe renal impairment, 24 hour CLCR <30 not requiring dialysis
  • Have a history of stable renal impairment as determined by standard estimated creatinine clearance methodology (at least 1 month within the same descriptive cohort) and be in a stable physical condition based on findings of medical history.
  • Women of childbearing potential must agree to use 1 of the following methods of birth control from the date they sign the ICF until two months after the last dose of study drug:

    1. Abstinence, when it is in line with the preferred and usual lifestyle of the subject. Subject agrees to use an acceptable method of contraception should they become sexually active.
    2. Maintenance of a monogamous relationship with a male partner who has been surgically sterilized by vasectomy (the vasectomy procedure must have been conducted at least 60 days prior to the Screening Visit or confirmed via sperm analysis).
    3. Barrier method (e.g., condom or occlusive cap) with spermicidal foam/gel/film/cream AND either hormonal contraception (oral, implanted, or injectable) or an intrauterine device or system.

Exclusion Criteria:

  • Subject has history of any concurrent medical condition which, in the opinion of the investigator, significantly increases the potential risks associated with administration of MTP-131 or any other aspect of study participation, with the exception of renal impairment.
  • Female subjects who are pregnant, planning to become pregnant, or lactating.
  • Subject has history of cancer (with the exception of non-melanoma skin cancer), unless the subject has documentation of completed curative treatment
  • Subject has history of renal transplantation.
  • Subject has active inflammatory renal disease.
  • Subject has a history of histamine intolerance (e.g., a known deficiency of endogenous or exogenous histamine degradation).
  • Subject is currently receiving treatment with chemotherapeutic agents or immunosuppressant agents.
  • Subject has positive serology for HIV 1, HIV 2, HBsAg or HCV.
  • Subject has donated or received blood or blood products within the past 30 days.
  • Subject participated in a clinical study involving investigational product within 30 days prior to the planned date of study drug administration.
  • Subject has a history of clinically significant hypersensitivity or allergy to any of the excipients contained in the study drug.
  • Subject has a history of active alcoholism or drug addiction during the year before the Screening Visit.

    • Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02436447


Locations
Layout table for location information
United States, Florida
Maimi, Florida, United States
Sponsors and Collaborators
Stealth BioTherapeutics Inc.

Layout table for additonal information
Responsible Party: Stealth BioTherapeutics Inc.
ClinicalTrials.gov Identifier: NCT02436447     History of Changes
Other Study ID Numbers: SPICP-101
First Posted: May 6, 2015    Key Record Dates
Last Update Posted: November 18, 2015
Last Verified: November 2015

Keywords provided by Stealth BioTherapeutics Inc.:
Renal Impairment, Renal function, MTP-131, Bendavia™

Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases